Home > Healthcare > Medical Devices > Therapeutic Devices > Topical Wound Agents Market

Topical Wound Agents Market Trends

Report ID: GMI7712
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Topical Wound Agents Market Trends

The increasing number of surgical procedures worldwide is leading to a higher demand for wound care products, including topical wound agents, to prevent surgical site infections and promote rapid healing. As surgical treatments become more accessible and affordable globally, more surgeries are estimated to be performed, leading to a higher demand for wound care products. Moreover, technological advancements in surgical techniques and the availability of advanced wound care, which accounted for USD 11.3 billion in 2023.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for topical wound agents was valued at USD 1.7 billion in 2023 and is estimated to reach USD 3.4 billion by 2032, owing to the rising prevalence of both chronic and acute wounds.

The chronic wound segment accounted for 79% market share in 2023, driven by the need to address specific challenges associated with diabetic ulcers, reduce complications, and promote effective wound healing in individuals with diabetes.

U.S. market accounted for USD 710 million revenue size in 2023, backed by aging population in the region, having slow wound healing and skin issues, creating a higher demand for wound care solutions.

Smith & Nephew plc., Teva Pharmaceutical Industries Ltd., Mölnlycke Health Care AB, 3M Company, Medline Industries, Inc., Arch Therapeutics, Inc. Mylan N.V., AstraZeneca and Osiris Therapeutics, Inc.